AbbVie has consolidated its leading position in the field of migraine with positive phase III study results on the treatment of menstrual migraines with atogipam.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.